IMVT - NASDAQ

Immunovant, Inc.

Immunovant, Inc.

IMVTยทNASDAQ

$31.15

+1.2%
HealthcareBiotechnology

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$6.40B
EPS-2.7700
P/E Ratio-11.25
Earnings Date06/04/2026
Immunovant, Inc.

Immunovant, Inc. Fair Value Envelope

IMVT ยท NASDAQ

Our analysis suggests that IMVT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.15, this represents a potential HIDDEN relative to our calculated worth for Immunovant, Inc..

HIDDEN
Intrinsic Value
Current Price: $31.15

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.9B
+ Cash & Equivalents$902.1M
Firm Value-$956.1M
- Debt$72.0K
Equity Value-$956.2M
/ Shares Outstanding175,276,526B
DCF Value-$5
OVERVALUED BY 118%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$374.1M
-$343.6M
-$315.6M
-$289.9M
-$266.3M
-$244.6M
-$224.7M
-$206.4M
-$189.6M
-$174.1M
Maintenance CapEx
-$1.5K
-$1.3K
-$1.2K
-$1.1K
-$1.0K
-$961
-$883
-$811
-$745
-$684
Owner Earnings
-$374.1M
-$343.6M
-$315.6M
-$289.9M
-$266.3M
-$244.6M
-$224.7M
-$206.4M
-$189.6M
-$174.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$346.4M
-$294.6M
-$250.6M
-$213.1M
-$181.2M
-$154.1M
-$131.1M
-$111.5M
-$94.8M
-$80.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IMVT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.